COVID-19 can directly cause neurologic symptoms and long-term neurological disease.
Elevations of blood biomarkers indicative of brain injury have been reported in the blood of COVID-19 patients.
In a new review study, researchers found that blood biomarkers can be used to improve the medical management of COVID-19 patients.
The research was conducted by a team at Banyan Biomarkers.
The COVID-19 pandemic poses big risks for acute and persistent brain deficits, as well as possible increased risk for brain diseases.
The use of blood biomarkers of brain injury integrated with additional existing diagnostic tools with big dataset analytics could provide timely, cost-effective approaches to address this issue.
In the study, the team reviewed the increased risks of the COVID-19 patient for persistent neurological deficits, psychiatric disorders, and potentially neurodegenerative diseases.
They also described mechanisms of the central neural system penetrance and action of the virus.
The study provides not only an assessment of the challenges presented by the effects of COVID-19 on the brain but also specific recommendations to address them.
In all, this team argues that many of the technologies needed to probe the effects of the COVID-19 virus on the brain are in hand and can be rapidly applied.
One author of the study is Ronald Hayes, Ph.D.
The study is published in the Journal of Neurotrauma.
Copyright © 2020 Knowridge Science Report. All rights reserved.
